Media kit
Keith Robins
Founder, The Bio Logic Foundation · Host, The Bio Logic Show · Bozeman, Montana
Keith Robins is the founder of The Bio Logic Foundation in Bozeman, Montana, and host of The Bio Logic Show. A lifelong entrepreneur, he built the Foundation’s Bonded Lot program, independent lot testing for research peptides launching in November 2026, after finding he could not match a seller’s certificate of analysis to the vial in his mailbox.
In one sentence
Bonded Lot is an independent program that has research-peptide lots tested double-blind by outside laboratories and publishes every result, permanently, whether or not the seller likes it.
Speaking topics
- The certificate arms race. Why a certificate of analysis supplied by the seller can’t settle anything, however honest the seller.
- Who picked the lab? How double-blind testing works, and why it changes which result you can believe.
- What is actually in the vial. What independent testing can and cannot tell a buyer, and why it never says “safe”.
- Building a certification mark from nothing. A buyer, not a chemist; a solo build; rules written before the first customer.
- Publish regardless. Why permanent public results are the only kind worth having, and what that costs the certifier.
- The state of the research-use-only peptide market. Who is selling, who is buying, and how quality is and isn’t checked today.
- The evolving FDA rules. What is changing around research-use-only peptides, and what it means for buyers and sellers.
Suggested questions
- What happened with your first order that sent you down this road?
- Every seller posts a certificate of analysis now. Why doesn’t that settle anything?
- What does “double-blind” mean when the thing being tested is a vial of peptides?
- Sellers pay for the testing. Why should anyone believe the result?
- What happens to a result the seller would rather nobody saw?
- What can an independent test tell a buyer, and what can it never tell them?
- The FDA sent warning letters to peptide vendors in August. What is changing in this market?
- You’re not a chemist. Why are you the one building this?
Three facts
An analytical laboratory testing peptide vials reported problems in almost 30% of the samples it analyzed: mislabeled, underdosed, overdosed or contaminated.
On 24 August 2026 the FDA sent warning letters to five online peptide vendors, finding that “research use only” labels did not outweigh websites that marketed the products for human use.
The illicit peptide market is estimated at up to $3 billion a year, and US imports of hormone and peptide compounds from China doubled in 2025, to $328 million in nine months.
Forbes, 22 July 2026; The New York Times, 3 January 2026 (US customs data)